Germline mutations in succinate dehydrogenase B (SDHB) predispose to hereditary paraganglioma (PGL) syndrome type 4. The risk of developing PGL or pheochromocytoma (PHEO) in SDHB mutation carriers is subject of recent debate. In the present nationwide cohort study of SDHB mutation carriers identified by the clinical genetics centers of the Netherlands, we have calculated the penetrance of SDHB associated tumors using a novel maximum likelihood estimator. This estimator addresses ascertainment bias and missing data on pedigree size and structure. A total of 195 SDHB mutation carriers were included, carrying 27 different SDHB mutations. The 2 most prevalent SDHB mutations were Dutch founder mutations: a deletion in exon 3 (31% of mutation carriers) and the c.423+1G>A mutation (24% of mutation carriers).
The mutation spectrum is dominated by a limited number of Dutch founder mutations, predominantly in SDHD but also in SDHB and SDHAF2. 3 In contrast to SDHD and SDHAF2 mutation carriers, SDHB mutation carriers are reported to develop metastatic PGLs more frequently. [4] [5] [6] [7] [8] [9] Germline mutations in SDHB are transmitted in an autosomal dominant way with incomplete penetrance. The reported penetrance of SDHB mutations varies widely (9%-75%) and is lower than the penetrance of (paternally inherited) SDHD or SDHAF2 mutations (88%-100% and 87%-100%, respectively). 7, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The majority of earlier series on the penetrance of SDHB mutations are largely based on cohorts of symptomatic PGL patients and a limited number of asymptomatic family members. The resulting overrepresentation of affected individuals and the fact that close case relatives tend to share additional genetic and/or environmental risk factors may lead to an overestimation of disease risk (ascertainment bias). Recent single-family-based studies that involve a more comprehensive screening and surveillance of asymptomatic family members of index patients have shown lower penetrance estimates for SDHB mutations. [18] [19] [20] An important limitation of single-family studies is that the outcome is based on 1 specific SDHB mutation, and the results of penetrance calculations may not be representative for carriers of other SDHB mutations.
In addition to the limited inclusion of asymptomatic mutation carriers, the insights into adequate methodology for penetrance calculations have also progressed over time. In earlier penetrance studies, Kaplan-Meier estimators were used to describe the penetrance. In order to correct for the ascertainment bias, index patients were left out of the analysis. This method is prone to bias especially in low-penetrant disease, as it discards a relatively large amount of valuable information of affected mutation carriers. It furthermore does not actually correct for the way family members are ascertained, because the reason these family members come under medical attention remains in the fact that they are part of a family with at least one affected family member.
Here, we present the age-related penetrance of SDHB mutations carriers identified in the clinical genetics centers in the Netherlands in a nationwide study. By the inclusion of SDHB mutation carriers using the registries of the clinical genetics centers, rather than through the tertiary referral centers that treat PGL patients, we were able to include carriers of germline mutations in SDHB in the Netherlands irrespective of their symptomatology. Moreover, we used a novel maximum likelihood estimator for the penetrance calculations, which allows for correction of the ascertainment bias and missing pedigree data using index patients, non-index patients and diseasefree mutation carriers. In addition, we compare the penetrance estimates for different SDHB mutation subgroups and for male and female mutation carriers. Screening for SDHB mutations was performed by direct sequencing using the Sanger method on an ABI 3777 Genetic Analyzer (Applied Biosystems, Carlsbad, California) and by multiplex ligation-dependent probe amplification (MLPA) using the P226 MLPA kit (MRC Holland, Amsterdam, the Netherlands). SDHB germline variants are classified as in the international guidelines by Plon et al. 23 In this manuscript we report pathogenic or probably pathogenic variants, including missense mutations in highly conserved regions that are probably pathogenic, as germline mutations.
| MATERIALS AND METHODS
Mutation carriers were investigated for the occurrence of PGL and/or PHEO according to structured protocols used for standard care
in the Netherlands for patients with a PGL or PHEO. 24 
| Statistics
The cohort consisted of index patients (defined as PGL/PHEO patients with a negative family history) and their relatives (SDHB mutation carriers with a positive family history who were assumed to be identified via an index patient and not by the presence of a tumor indicative of PGL syndrome). All individuals in the data set carried a germline mutation in the SDHB gene. The maximum likelihood estimates were determined for the penetrance for all mutations together and for 3 genotypic subgroups separately (patients linked to a deletion exon 3, patients linked to the c.423+1G>A mutation and the remainder mutations in SDHB, respectively). In addition, maximum likelihood estimates were determined for males and females separately. The penetrance function was assumed to equal Weibull distributions with unknown shape and scale parameters. This novel method for the calculation of the penetrance function is described in more detail in Appendix S1, Supporting Information. The likelihood ratio test was used to test for differences between the penetrance functions of males and females, and between the penetrance functions of the 3 genotypic subgroups. Based on the data of all SDHBlinked patients (index or non-index), the age-at-diagnosis distribution was estimated for all mutations together, for 3 genotypic subgroups separately, and for males and females separately, by their empirical distribution functions. The log rank test was used to test for differences between the age-at-diagnosis distributions of these subgroups.
IBM SPSS Statistics version 20.0 (SPSS Inc., Chicago, Illinois) and the statistical package R, version 3.0.1 were used for data analysis.
Results were expressed as mean AE SD.
| RESULTS
In all, 195 SDHB germline mutation carriers were identified and included in the study, 83 men (42.6%) and 112 women (57.4%), carrying 27 distinct SDHB mutations ( 
| Penetrance
The estimated penetrance of SDHB mutations for PGL and PHEO is shown in Figure 1 . The overall penetrance is 0.064 at age We did not find a statistically significant difference in the penetrance between different SDHB mutations, that is, the Dutch SDHB exon 3 founder deletion, the Dutch SDHB founder mutation c.423
+1G>A, and the other mutations in SDHB grouped together (likelihood ratio test P = .740) (Figure 2A ). We also did not find a statistically significant difference in the SDHB-linked penetrance between male and female mutation carriers (likelihood ratio test P = .368) ( Figure 2B ).
| Age at diagnosis
The estimated age distribution for the diagnosis of the first index tumor of PGL/PHEO patients is shown in Figure 3 . Figure 4A shows the age at diagnosis for the 3 genotypic subgroups: PGL/PHEO patients linked to a deletion in exon 3, patients linked to the c.423
+1G>A mutation, and all remainder mutations in SDHB, respectively.
We did not find a significant difference in the age at diagnosis between these genetic subgroups (log rank test P = .462).
| DISCUSSION
The risk of developing PGL/PHEO for SDHB germline mutation carriers has been the subject of recent debate, and varying penetrance estimates have been reported. Establishing the true penetrance of SDHB mutations is critical for proper counseling of SDHB germline mutation carriers. In this nationwide study, we found an estimated age-dependent SDHB-linked penetrance of 21% at 50 years.
In addition we have compared the penetrance of different SDHB mutation subgroups. We found no significant differences in the penetrance estimates of the genotypic subgroups, that is, the 2 most prevalent Dutch founder mutations (the c.423+1G>A splice site mutation and an exon 3 deletion) and all other SDHB mutations grouped together ( Table 1) . As both founder mutations represent different mutation types (a missense mutation and an exon deletion), these results therefore seem applicable to SDHB mutations in general a This individual underwent presymptomatic testing (PST) because of positive family history, however, the index patient of this individuals' family was not tested in the Netherlands.
( Figure 2A ). We also did not find a statistically significant difference in penetrance for male and female SDHB mutation carriers, despite a reported higher incidence of PGL in women ( Figure 2B ). 1, 26 This reported higher incidence in women is therefore probably not a feature of SDHB mutations, but may be a feature of other PGL/PHEO susceptibility genes.
In earlier studies, an overall penetrance of SDHB mutations was estimated to be as high as 50%-75% at 50 years. These studies were largely based on affected, apparently non-familial individuals. 4, 7, 13 Family-based studies generally allow for more adequate identification of asymptomatic mutation carriers by means of family screening, and thus more accurate penetrance estimates for single mutations. Recent studies in SDHB-linked families report penetrance estimates of 9%-35% by the age of 50 years. [18] [19] [20] The disadvantage of studies of single families is the fact that those results are based on 1 specific SDHB mutation, and may not represent the penetrance of other SDHB mutations. In this study, comprising virtually all known SDHB mutation carriers in the Netherlands, carrying a total of 27 different SDHB mutations, a relatively large number of asymptomatic SDHB mutation carriers (112/195) could be included because of the acquisition through clinical genetics centers, rather than through medical centers. In this way, the ascertainment bias is decreased, resulting in a more accurate penetrance estimate for SDHB mutations.
In order to further reduce bias, we did not use a standard Kaplan-Meier estimator for the calculation of the penetrance function, a method used in most early reports on germline SDHB mutations. 4, 7, 13 These estimators are prone to overestimation because they do not adequately correct for the ascertainment bias. 16 The frequently used method for correcting this source of bias, that is, leaving the index patients out of the analysis, does not actually correct for the way the mutation carriers remaining in the analysis are ascertained. These mutation carriers are identified because they are family members of index patients, and thus are probably to share environmental and genetic risk factors. An additional disadvantage of leaving index patients out of the analysis, especially in rare and low-
The maximum likelihood estimate of the age-related penetrance of SDHB mutations for paraganglioma and/or pheochromocytoma (continuous line) and 95% confidence interval (dashed line). More recent studies have used a maximum likelihood methodology to correct for the ascertainment bias, reporting lower SDHBlinked penetrance estimates of 9%-13% at 50 years. 16, 20 These studies were family-based, and thus were able to use information of the family pedigrees. In the current cohort-based study, the information on pedigree size and structure is largely missing. Only individuals that underwent genetic testing are included in the analysis, untested family members at risk or obligate mutation carriers could not be identified, a common disadvantage of studies that are not family-based.
This may lead to overestimation of disease risk because it is probably that healthy individuals without complaints are less inclined to consent to genetic testing than individuals with signs or symptoms indicative of PGL syndrome. Individuals that did undergo genetic testing are probably to be predominantly members of the nuclear family of PGL patients, and case relatives tend to share possible additional genetic and/or environmental risk factors. Unfortunately, it is not possible to reliably assess the number of individuals at risk who did not undergo genetic analysis.
We designed a maximum likelihood estimator to quantify the effect of the missing data on the pedigree size and structure on penetrance estimates (see Appendix S1). This statistical method is not a missing, using the data of all affected and unaffected SDHB germline mutation carriers, including index patients. Using this maximum likelihood estimator on our nationwide cohort of SDHB mutation carriers (including a relatively large number of disease-free mutation carriers), our penetrance estimates are lower than previously reported in cohort-based studies.
In conclusion, the current best estimate of the penetrance of SDHB-linked PGL/PHEO syndrome is 21% at 50 and 42% at 70 years of age. We find no difference in the penetrance of PGL and PHEO between different SDHB germline mutations, nor between male and female SDHB mutation carriers. 
